✦ LIBER ✦

P.39 Docetaxel plus epirubicin (DE) vs docetaxel plus capecitabine (DC) as 1st line treatment in patients with locally advanced and metastatic breast cancer: a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)

✍ Scribed by Vamvakas, L.; Karampeazis, A.; Ardavanis, A.; Souglakos, I.; Kalbakis, K.; Vardakis, N.; Kouroussis, Ch.; Malamos, N.; Varthalitis, I.; Mavroudis, D.

Book ID: 122752725
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 57 KB
Volume: 64
Category: Article
ISSN: 1040-8428
DOI: 10.1016/S1040-8428(13)70212-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O12 FOLFOXIRI versus FOLFIRI as first li

O12 FOLFOXIRI versus FOLFIRI as first line treatment in metastatic colorectal cancer (MCC): a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)

✍ Vamvakas, L.; Androulakis, N.; Syrigos, K.; Polyzos, A.; Ziras, N.; Athanasiadis 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 62 KB

P.40 Oral vinorelbine and gemcitabine (o

P.40 Oral vinorelbine and gemcitabine (oVG) versus docetaxel and gemcitabine (DG) as first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis for elderly patients of a phase III randomized trial from the Hellenic Oncology Research Group (HORG)

✍ Vamvakas, L.; Karampeazis, A.; Agelaki, S.; Agelidou, A.; Kotsakis, A.; Kakolyri 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB